Incidence and clinical implications of late immune-related adverse events in long responders to PD-1/PD-L1 checkpoint inhibitors: A multicenter study

被引：0
|
作者：
Nigro, O. [1 ]
Cortellini, A. [2 ]
Giusti, R. [3 ]
Marchetti, P. [3 ]
De Galitiis, F. [4 ]
Di Pietro, F. R. [4 ]
Bersanelli, M. [5 ]
Lazzarin, A. [5 ]
Galetta, D. [6 ]
Pizzutillo, P. [6 ]
Santini, D. [7 ]
Torniai, M. [8 ]
De Giglio, A. [9 ]
Russo, A. [10 ,11 ]
Silva, R. R. [12 ]
Bolzacchini, E. [13 ]
Natoli, C. [14 ]
Rijavec, E. [15 ]
Vallini, I. [1 ]
Pinotti, G. [1 ]
机构：
[1] Osped Circolo Varese, ASST Sette Laghi, Med Oncol, Varese, Italy
[2] St Salvatore Hosp, Med Oncol, Laquila, Italy
[3] Azienda Osped Univ St Andrea, Med Oncol, Rome, Italy
[4] IRCCS, IDI, Oncol & Oncol Dermatol, Rome, Italy
[5] Azienda Osped Univ Parma, Med Oncol, Parma, Italy
[6] Clin Canc Ctr Giovanni Paolo II, Thorac Oncol Unit, Bari, Italy
[7] Campus Biomed, Med Oncol, Rome, Italy
[8] Univ Politecn Marche, Azienda Osped Univ Ospedali Riuniti Umberto I, Med Oncol, Ancona, Italy
[9] Osped S Maria Misericordia, Oncol Med, Perugia, Italy
[10] AO Papardo, Med Oncol, Messina, Italy
[11] Dept Human Pathol, Messina, Italy
[12] Area Vasta 2, ASUR Marche, Med Oncol, Fabriano, Italy
[13] Osped St Anna, ASST Lariana, Med Oncol, Como, Italy
[14] SS Annunziata Hosp, Med Oncol, Chieti, Italy
[15] Policlin Milano, Med Oncol, Milan, Italy
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
55P
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Early Immune-Related Adverse Events Under PD-1/PD-L1 Inhibitors Predict Better Progression-Free Survival in NSCLC
    Boussageon, M.
    Ortiz-Cuaran, S.
    Chabaud, S.
    Perol, D.
    Avrillon, V.
    Mastroianni, B.
    Fayette, J.
    Ghiringhelli, F.
    Neidhardt, E.
    Swalduz, A.
    Paulus, V.
    Kaderbhai, C.
    Fumet, J.
    Saintigny, P.
    Perol, M.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S407 - S407
  • [42] Pulmonary Immune-Related Adverse Events ofPD-1 Versus PD-L1 Checkpoint Inhibitors: A Retrospective Review of Pharmacovigilance
    Ebinama, Ugochi
    Sheshadri, Ajay
    Anand, Kartik
    Swaminathan, Iyer
    JOURNAL OF IMMUNOTHERAPY AND PRECISION ONCOLOGY, 2023, 6 (04) : 177 - 184
  • [43] Retrospective study of immune-related adverse events in NSCLC patients treated with PD-1 inhibitors
    Otsubo, Aya
    Ota, Takeshi
    Okajima, Masaaki
    Tanaka, Hiroshi
    Ishida, Takashi
    Iwashima, Akira
    Watanabe, Satoshi
    Sato, Kazuhiro
    Matsumoto, Naoya
    Miyabayashi, Takao
    Terada, Masaki
    Sato, Ko
    Ishikawa, Daisuke
    Tanabe, Yoshinari
    Yoshizawa, Hirohisa
    Kikuchi, Toshiaki
    ANNALS OF ONCOLOGY, 2019, 30
  • [44] Correlation of Immune-Related Adverse Events to Efficacy of PD-1/PD-L1 Inhibitors in Small Cell Lung Cancer: A Multi-center Retrospective Study
    Zhang, J.
    Gao, A.
    Li, J.
    Wang, S.
    Sun, H.
    Sun, Y.
    Cheng, Q.
    Wu, J.
    Ge, Y.
    Sun, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S689 - S689
  • [45] Can Immune-related adverse events serve as clinical biomarkers of PD-1/ PD-L1 inhibitor efficacy in Pan-Cancer Patients?
    Ye, Ziqi
    Zheng, Shiyu
    Chen, Jie
    Zhang, Yanfang
    Yang, Si
    Hong, Yun
    Yang, Hongyu
    Xuan, Zixue
    Zhao, Qingwei
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2022, 108
  • [46] Adverse Events of PD-1, PD-L1, CTLA-4, and LAG-3 Immune Checkpoint Inhibitors: An Analysis of the FDA Adverse Events Database
    Frey, Connor
    Etminan, Mahyar
    ANTIBODIES, 2024, 13 (03)
  • [47] PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
    Liu, Jinhua
    Chen, Zichao
    Li, Yaqun
    Zhao, Wenjie
    Wu, JiBiao
    Zhang, Zhen
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [48] PD-1/PD-L1 inhibitors related adverse events: A bibliometric analysis from 2014 to 2024
    Song, Qingya
    Yu, Zongliang
    Lu, Wenping
    Zhuo, Zhili
    Chang, Lei
    Mei, Heting
    Cui, Yongjia
    Zhang, Dongni
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2025, 21 (01)
  • [49] Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
    Wang, Dongxu
    Lin, Jianzhen
    Yang, Xu
    Long, Junyu
    Bai, Yi
    Yang, Xiaobo
    Mao, Yilei
    Sang, Xinting
    Seery, Samuel
    Zhao, Haitao
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2019, 12 (1)
  • [50] Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
    Dongxu Wang
    Jianzhen Lin
    Xu Yang
    Junyu Long
    Yi Bai
    Xiaobo Yang
    Yilei Mao
    Xinting Sang
    Samuel Seery
    Haitao Zhao
    Journal of Hematology & Oncology, 12
12345